comparemela.com

Latest Breaking News On - British columbia cognitive complaints inventory - Page 1 : comparemela.com

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed.

United statesUnited kingdomNew yorkKarl doghramjiDarren oplandMark jacobsonAxsome therapeutics incNarcolepsy networkWorld trade centerCorporate communicationsDrug administrationEpworth sleepiness scaleBritish columbia cognitive complaints inventoryCharacterizing patient perspectivesUnmet needsMedical director

Survey Sheds Light on Narcolepsy Treatment Challenges

Axsome Therapeutics' CRESCENDO survey finds 77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated.

United kingdomVesalainen dreamstimeKarl doghramjiNarcolepsy networkAxsome therapeuticAxsome therapeuticsCharacterizing patient perspectivesUnmet needsEpworth sleepiness scaleBritish columbia cognitive complaints inventoryJefferson sleep disorders centerThomas jefferson universityTopline findingsTero vesalainenDrug administration approved

Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023

Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apneaNEW YORK, June 01, 2023 Axsome Therapeutics, Inc. , a. | June 1, 2023

United kingdomUnited statesNew yorkDarren oplandHans van dongenJohannes gutenbergMark jacobsonRussell rosenbergResearch societyWorld trade centerDrug administrationNeurotrials researchCorporate communicationsProfessor at washington state universityUs drug enforcement agency onSk biopharmaceuticals co ltd

Axsome Presents New Data for Solriamfetol in SHARP Study

Axsome is sharing data from a study of solriamfetol in 59 patients with EDS associated with OSA and impaired cognitive function.

United statesUnited kingdomHans van dongenDrug administrationAmerican academy of neurologyUs drug enforcement agency onProfessor at washington state universityAxsome therapeuticsCognitive healthApnea participants duringRandomized placebo controlledAnnual meetingBritish columbia cognitive complaints inventoryEpworth sleepinessWashington state universityEnforcement agency

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting

NEW YORK, April 21, 2023 Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today. | April 21, 2023

United statesUnited kingdomNew yorkMark jacobsonStuartj tepperAxsome moDarren oplandEileen learyZachariah thomasSamantha floamHans van dongenSk biopharmaceuticals co ltdAffairs at axsomeClinical development at axsomeAxsome therapeutics incGeisel school of medicine at dartmouth

vimarsana © 2020. All Rights Reserved.